Tatsuya Sasaki

A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.

K. Nakano, M. Tahara, H. Minami, 2019, Future oncology.

Post-Marketing Surveillance of Amrinone (Amcoral® Injection 50·100)

K. Gomi, Keiji Tanaka, T. Takano, 2004 .

Lenvatinib for Anaplastic Thyroid Cancer

K. Nakano, M. Tahara, H. Minami, 2017, Front. Oncol..

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors

H. Wakui, T. Tamura, Yasuhide Yamada, 2015, Cancer Chemotherapy and Pharmacology.

First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors

Toshio Shimizu, A. Shimomura, K. Yonemori, 2019, Cancer science.

Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.

K. Nakano, M. Tahara, H. Minami, 2016 .